Iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors: A single-arm, multicenter, pivotal, phase II study

被引：0
|
作者：
Guo, Weijian
Bi, Feng
Dong, Jian
Jin, Chuan
Niu, Zuoxing
Wang, Yusheng
Sun, Meili
Wang, Teng
Yu, Dajun
He, Yifu
Zhang, Ruixing
Yin, Xianli
Feng, Wenlei
Zhang, Meijiang
Zhang, Baihui
Li, Lingyan
Kang, Xiaoyan
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Gastrointestinal Oncol, Shanghai, Peoples R China
[2] Sichuan Univ, Dept Abdominal Oncol, West China Hosp, West China Sch Med, Chengdu, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China
[4] Guangzhou Med Univ, Affiliated Tumor Hosp, Guangzhou, Peoples R China
[5] Shandong Canc Hosp, Jinan, Peoples R China
[6] Shanxi Canc Hosp, Taiyuan, Peoples R China
[7] Shandong First Med Univ, Dept Oncol, Cental Hosp, Dept Oncol, Jinan, Peoples R China
[8] Jiangnan Univ, Affiliated Hosp, Dept Oncol, Wuxi Peoples Hosp 4, Wuxi, Jiangsu, Peoples R China
[9] Bengbu Med Coll, Affiliated Hosp 1, Surg Oncol, Bengbu, Peoples R China
[10] Anhui Prov Canc Hosp, Hefei, Peoples R China
[11] Hebei Med Univ, Hebei Canc Hosp, Hosp 4, Dept Gastroenterol, Shijiazhuang, Hebei, Peoples R China
[12] Hunan Canc Hosp, Changsha, Peoples R China
[13] Qilu Pharmaceut Co Ltd, Dept Oncol, Jinan, Peoples R China
[14] Qilu Pharmaceut Co Ltd, Clin Res Ctr, Jinan, Peoples R China
[15] Qilu Pharmaceut Co Ltd, Clin Res Ctr, Jinan, Shandong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3578
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II, open-label, single-arm study of QL1604 plus paclitaxel-cisplatin/carboplatin as first-line treatment in patients with recurrent or metastatic cervical cancer
    Liu, J.
    Fang, C.
    Zhou, Q.
    He, L.
    Yu, J.
    Li, Y.
    Feng, M.
    Pan, M.
    Zhao, L.
    Tang, D.
    Li, X.
    Tan, B.
    An, R.
    Zheng, X.
    Si, M.
    Zhang, B.
    Li, L.
    Kang, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1506 - S1506
  • [42] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
    Overman, Michael J.
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Atasoy, Ajlan
    Zhao, Huanyu
    Lei, Ming
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [43] Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer
    Cercek, Andrea
    Bachet, Jean-Baptiste
    Capdevila, Jaume
    Starling, Naureen
    Xueyu Chen, Eric
    Di Bartolomeo, Maria
    Yoshino, Takayuki
    Vlahovic, Gordana
    Zografos, Eleftherios
    O'Donnell, Sean
    Szijgyarto, Zsolt
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
    Andre, T.
    Amonkar, M.
    Norquist, J.
    Shiu, K-K.
    Kim, T. W.
    Jensen, B. V.
    Jensen, L. H.
    Punt, C. J.
    Smith, D.
    Garcia-Carbonero, R.
    Sevilla, I.
    de la Fouchardiere, C.
    Rivera, F.
    Elez, E.
    Diaz, L. A.
    Yoshino, T.
    Van Cutsem, E.
    Yang, P.
    Farooqui, M. Z. H.
    Le, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S409 - S409
  • [45] NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase 3 Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination vs Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (NCT02997228).
    不详
    ONCOLOGY-NEW YORK, 2021, 35 (06): : 367 - 367
  • [46] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [47] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
    Shiu, K. K.
    Andre, T.
    Kim, T. W.
    Jensen, B. Vittrup
    Jensen, L. H.
    Punt, C. J. A.
    Smith, D.
    Garcia-Carbonero, R.
    Alcaide-Garcia, J.
    Gibbs, P.
    De la Fouchardiere, C.
    Rivera, F.
    Fernandez, M. E. Elez
    Le, D. T.
    Yoshino, T.
    Zuo, Y.
    Fogelman, D.
    Adelberg, D. E.
    Diaz, L. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1271 - S1272
  • [48] PATIENT-REPORTED OUTCOMES (PROS) IN THE GARNET TRIAL IN PATIENTS (PTS) WITH ADVANCED OR RECURRENT MISMATCH REPAIR DEFICIENT/MICROSATELITE INSTABILITY-HIGH (DMMR/MSI-H) ENDOMETRIAL CANCER (EC) TREATED WITH DOSTARLIMAB
    Kristeleit, Rebecca
    Mathews, Cara
    Redondo, Andres
    Huang, Joice
    Eliason, Laurie
    Im, Ellie
    Brown, Jubilee
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A40 - A41
  • [49] Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
    Kristeleit, R.
    Matthews, C.
    Redondo, A.
    Huang, J.
    Eliason, L.
    Im, E.
    Brown, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S637 - S637
  • [50] A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Li, Zhezhen
    Wang, Huanli
    Liu, Shou
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345